Allegiance Research Specialists

Milwaukee based Clinical Research expertise in Allergy/Immunology, Cardiology, Dermatology, Gastroenterology, Internal Medicine, Ophthalmology, Neurology, Psychiatry, Urology, Women's Health, and Radiology - Leading many of the most ground breaking cutting edge research trials!

We are currently enrolling participants in the following studies:
Ulcerative Colitis
• Takeda (Vedolizumab) Protocol MLN 0002-3026
o Title: An Efficacy and Safety Study of Vedolizumab (Entyvio) Intravenous (IV) Compared to Adalimumab (Humira) Subcutaneous (SC) in Participants With Ulcerative Colitis
o Purpose: The purpose of this study is to evaluate the efficacy and safety of vedolizumab intravenous (IV) treatment compared to adalimumab subcutaneous (SC) treatment over a 52-week treatment period.
o More info: http://bit.ly/2bYpGKE

• Arena (APD334) Protocol APD334-003
o Safety and Efficacy of APD334 in Patients With Ulcerative Colitis
o Purpose: The purpose of this study is to determine whether APD334 is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.
o More info: http://bit.ly/2cp2TXJ

• Gilead / ICON (GS-5745) Protocol GS-US_326-1100
o Safety and Efficacy of GS-5745 in Adults With Moderately to Severely Active Ulcerative Colitis
o Purpose: This study will evaluate the efficacy, safety, and tolerability of GS-5745.
o More info: http://bit.ly/2bU6n6Q

Crohn's
• Takeda (Vedolizumab) Protocol MLN 3031
o Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
o Purpose: The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab SC) as maintenance treatment in participants with moderately to severely active Crohn's disease (CD) who achieved clinical response following administration of vedolizumab intravenous (vedolizumab IV) induction therapy.
o More info: http://bit.ly/2bU7l33

• MedImmune (MEDI2070) Protocol D5170C00002
o Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease
o Purpose: A Phase 2b study to evaluate the efficacy and safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
o More Info: http://bit.ly/2chVzzS